Octreotide · source year
6 selected, source-linked Octreotide records carrying a 2020 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
6 selected records.
2 represented types.
6 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02916433 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-08, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04129255 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-10, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 208232 with status AP dated 2020-06-26, and names octreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00002864 at 2026-07-30T20:29:13.581Z. Its registry update date was 2020-04-01, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04281680 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-24, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00226967 at 2026-07-30T20:33:20.622Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗